Abstract
Background: Docetaxel-induced peripheral neuropathy (PN) is typically manifested as sensory and motor neuropathy. This study aimed to investigate the incidence, duration, and risk factors of sensory and motor PN and their impact on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy. Methods: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients. Results: Cumulative incidence rates of motor and sensory PN were 31.5 and 21.3%, while the median durations of motor and sensory PN were 6 and 13 weeks. A consistently significant risk factor for both PNs was a cumulative docetaxel dose of >300 mg/m2. A significant interaction between sensory PN and time was found for physical and social functioning, while a significant motor PN and time interaction effect was identified for physical functioning only. Conclusions: Motor PN was more common than sensory PN in BC patients treated with docetaxel. Both types of PN had a significant impact on physical functioning.
References
1.
De Iuliis
F
, Taglieri
L
, Salerno
G
, Lanza
R
, Scarpa
S
. Taxane induced neuropathy in patients affected by breast cancer: literature review
. Crit Rev Oncol Hematol
. 2015
Oct
;96
(1
):34
–45
.
[PubMed]
1040-84282.
Mols
F
, Beijers
T
, Vreugdenhil
G
, van de Poll-Franse
L
. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review
. Support Care Cancer
. 2014
Aug
;22
(8
):2261
–9
.
[PubMed]
0941-43553.
Speck
RM
, Sammel
MD
, Farrar
JT
, Hennessy
S
, Mao
JJ
, Stineman
MG
, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer
. J Oncol Pract
. 2013
Sep
;9
(5
):e234
–40
.
[PubMed]
1554-74774.
Osmani
K
, Vignes
S
, Aissi
M
, Wade
F
, Milani
P
, Lévy
BI
, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation
. J Neurol
. 2012
Sep
;259
(9
):1936
–43
.
[PubMed]
0340-53545.
Stubblefield
MD
, Burstein
HJ
, Burton
AW
, Custodio
CM
, Deng
GE
, Ho
M
, et al. NCCN task force report: management of neuropathy in cancer
. J Natl Compr Canc Netw
. 2009
Sep
;7
Suppl 5
:S1
–26
.
[PubMed]
1540-14056.
Eckhoff
L
, Knoop
A
, Jensen
MB
, Ewertz
M
. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors
. Eur J Cancer
. 2015
Feb
;51
(3
):292
–300
.
[PubMed]
0959-80497.
Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst 2018;110(2):djx162.
8.
Molassiotis
A
, Cheng
HL
, Lopez
V
, Au
JS
, Chan
A
, Bandla
A
, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
. BMC Cancer
. 2019
Feb
;19
(1
):132
.
[PubMed]
1471-24079.
Molassiotis
A
, Cheng
HL
, Leung
KT
, Li
YC
, Wong
KH
, Au
JS
, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy
. Brain Behav
. 2019
Jun
;9
(6
):e01312
.
[PubMed]
2162-327910.
Cheng
HL
, Molassiotis
A
. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx)
. Asia Pac J Clin Oncol
. 2019
Feb
;15
(1
):56
–62
.
[PubMed]
1743-755511.
US Department of Health and Human Services
. National Cancer Institute.
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. https://evs.nci.nih.gov/ftp1/CTCAE/About.html;2010 [Accessed 19 June 2019]12.
Cavaletti
G
, Cornblath
DR
, Merkies
IS
, Postma
TJ
, Rossi
E
, Frigeni
B
, et al.; CI-PeriNomS Group
. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
. Ann Oncol
. 2013
Feb
;24
(2
):454
–62
.
[PubMed]
0923-753413.
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41(8):1135-1139.14.
14.
Aaronson
NK
, Ahmedzai
S
, Bergman
B
, Bullinger
M
, Cull
A
, Duez
NJ
, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology
. J Natl Cancer Inst
. 1993
Mar
;85
(5
):365
–76
.
[PubMed]
0027-887415.
Tofthagen C, McAllister RD, Visovsky C. Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J Adv Pract Oncol 2013;4(4):204-215.16.
16.
Pereira
S
, Fontes
F
, Sonin
T
, Dias
T
, Fragoso
M
, Castro-Lopes
JM
, et al. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study
. Support Care Cancer
. 2016
Apr
;24
(4
):1571
–81
.
[PubMed]
0941-435517.
Simon
NB
, Danso
MA
, Alberico
TA
, Basch
E
, Bennett
AV
. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice
. Qual Life Res
. 2017
Oct
;26
(10
):2763
–72
.
[PubMed]
0962-934318.
Kus
T
, Aktas
G
, Kalender
ME
, Sevinc
A
, Kul
S
, Suner
A
, et al. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study
. Support Care Cancer
. 2016
Mar
;24
(3
):1175
–9
.
[PubMed]
0941-435519.
Frigeni
B
, Piatti
M
, Lanzani
F
, Alberti
P
, Villa
P
, Zanna
C
, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale
. J Peripher Nerv Syst
. 2011
Sep
;16
(3
):228
–36
.
[PubMed]
1085-948920.
Bottomley
A
, Jones
D
, Claassens
L
. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency
. Eur J Cancer
. 2009
Feb
;45
(3
):347
–53
.
[PubMed]
0959-8049© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
